ライフサイエンスコーパス: carcinoembryonic

1 ombinant vaccinia virus expressing the human carcinoembryonic Ag (CEA) in a murine FAP model in which

2 Antitumor experiments using a self-Ag (carcinoembryonic Ag (CEA) vaccines in CEA transgenic mic

3 Murine mAb COL-1 reacts with carcinoembryonic Ag (CEA), expressed on a wide range of

4 A carcinoembryonic Ag (CEA)-based DNA vaccine encoding bot

5 s immunogen, and in a "self" Ag model, using carcinoembryonic Ag as immunogen in carcinoembryonic Ag

6 revealed upregulation of gene expression for carcinoembryonic Ag cell adhesion molecule (CEACAM) fami

7 n this study, we identify the NET-associated carcinoembryonic Ag cell adhesion molecule 1 (CEACAM1) a

8 Carcinoembryonic Ag cell adhesion molecule 1 (CEACAM1) c

9 equire costimulation through a member of the carcinoembryonic Ag family present on early gestation tr

10 ule CD1d and a costimulatory molecule of the carcinoembryonic Ag family present on the intestinal epi

11 Four members of the carcinoembryonic Ag family, CD66a, CD66b, CD66c, and CD6

12 al capacity of the MFEzeta CAR to respond to carcinoembryonic Ag protein Ag.

13 Repeated vaccination with this carcinoembryonic Ag SLP in mice shows improved T cell re

14 highly glycosylated protein belonging to the carcinoembryonic Ag supergene family.

15 l, using carcinoembryonic Ag as immunogen in carcinoembryonic Ag transgenic mice.

16 D) has been derived from an epitope in human carcinoembryonic Ag, CEA(605-613) (Cap1).

17 type and analogue peptides derived from p53, carcinoembryonic Ag, Her2/neu, and MAGE2/3 were screened

18 Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells

19 d altered peptide ligand can induce distinct carcinoembryonic Ag-reactive T cells with different func

20 The long cytoplasmic tail (CT) isoforms of carcinoembryonic Ag-related cell adhesion molecule 1 (CE

21 Recent results showed that carcinoembryonic Ag-related cell adhesion molecule 1 (CE

22 Carcinoembryonic Ag-related cellular adhesion molecule 1

23 Carcinoembryonic Ag-related cellular adhesion molecule 1

24 The cell adhesion molecule, carcinoembryonic Ag-related cellular adhesion molecule 1

25 Jurkat T cell model system, expression of a carcinoembryonic Ag-specific CD3zeta CAR (MFEzeta) resul

26 icantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL.

27 formulations in mice using SLP derived from carcinoembryonic Ag.

28 recurrence were not significantly different: carcinoembryonic antigen (29.1% v 37.4%), computed tomog

29 biomarkers performed better than cyst fluid carcinoembryonic antigen (37%/80% sensitivity/specificit

30 he accuracy of standard analyses: cyst fluid carcinoembryonic antigen (61%; 95% CI, 46% to 74%; P < .

31 ncluding measurement of serum calcitonin and carcinoembryonic antigen (and their doubling times), in

32 Antibodies targeting carcinoembryonic antigen (Anti-CEA) were immobilized to

33 Lymphovascular invasion, preoperative serum carcinoembryonic antigen (CEA > 5 ng/mL) level, and age

34 h worse OS were node-positive primary tumor, carcinoembryonic antigen (CEA) >200 mug/L, and clinical

35 Risk factors for death were carcinoembryonic antigen (CEA) >80 mug/L, progressive di

36 used consisted of mice transgenic for human carcinoembryonic antigen (CEA) and a murine carcinoma ce

37 ted with TF2--a recombinant, humanized, anti-carcinoembryonic antigen (CEA) and anti-histamine-succin

38 In addition to carcinoembryonic antigen (CEA) and CA 15-3, CA 27.29 was

39 hemin aptamer), capable of rapidly capturing carcinoembryonic antigen (CEA) and hemin, an all-in-one

40 Promoters for the human carcinoembryonic antigen (CEA) and MUC1/DF3 tumor-associ

41 cal aptasensor for simultaneous detection of carcinoembryonic antigen (CEA) and neuron-specific enola

42 We and others have found high levels of carcinoembryonic antigen (CEA) and prostate-specific ant

43 tastatic cancer expressing the tumor antigen carcinoembryonic antigen (CEA) and that it overcame high

44 ed the Fc-FcRn binding site of chimeric anti-carcinoembryonic antigen (CEA) antibodies produced in a

45 In this study, we used an anti-carcinoembryonic antigen (CEA) antibody (MN-14) tagged w

46 For example, 2 identical Fabs reacting with carcinoembryonic antigen (CEA) are bound to a Fab reacti

47 Using carcinoembryonic antigen (CEA) as a model analyte, the p

48 Mice expressing human carcinoembryonic antigen (CEA) as a transgene (CEA.Tg) d

49 protein biomarker in undiluted serum, using carcinoembryonic antigen (CEA) as the test case.

50 or colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) be ordered preoperatively

51 l line LS174T, while measuring the biomarker carcinoembryonic antigen (CEA) before and after the use

52 CNT/AgNPs electrodes were applied to detect carcinoembryonic antigen (CEA) by measuring the end-prod

53 h prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs).

54 Calcitonin and carcinoembryonic antigen (CEA) doubling times are curren

55 As a tumor marker for colorectal cancers, carcinoembryonic antigen (CEA) enhances the metastatic p

56 l line specific for a MHC class I-restricted carcinoembryonic antigen (CEA) epitope, residues 526-533

57 Carcinoembryonic antigen (CEA) expression is used clinic

58 late (non-typeable) H. influenzae target the carcinoembryonic antigen (CEA) family of cell adhesion m

59 For the human carcinoembryonic antigen (CEA) family, a subfamily of th

60 CEACAM1 is a member of the carcinoembryonic antigen (CEA) family.

61 The release of soluble antigens, such as carcinoembryonic antigen (CEA) from colorectal carcinoma

62 When transgenic mice that express the human carcinoembryonic antigen (CEA) gene (CEA transgenic) wer

63 typic cell adhesion protein belonging to the carcinoembryonic antigen (CEA) gene family and expressed

64 been successfully used for the detection of carcinoembryonic antigen (CEA) in 30 muL of whole blood

65 , a label-free sensitive assay for detecting carcinoembryonic antigen (CEA) in a continuous and recyc

66 mplicated the surface glycoproteins CD44 and carcinoembryonic antigen (CEA) in adhesion, migration, a

67 experiment, detection of a cancer biomarker carcinoembryonic antigen (CEA) in blood plasma using ant

68 using an SPR biosensor for the detection of carcinoembryonic antigen (CEA) in which AuNPs covered wi

69 Carcinoembryonic antigen (CEA) is a tumor marker that is

70 Carcinoembryonic antigen (CEA) is a tumor-associated ant

71 Carcinoembryonic antigen (CEA) is an important oncomarke

72 By virtue of its tissue-specific expression, carcinoembryonic antigen (CEA) is an important self, tum

73 Human carcinoembryonic antigen (CEA) is an oncofetal glycoprot

74 Carcinoembryonic antigen (CEA) is highly expressed on th

75 Patients with a carcinoembryonic antigen (CEA) less than 200 ng/mL had i

76 proposed the inclusion of pretreatment serum carcinoembryonic antigen (CEA) levels (C stage) into the

77 Median total bilirubin, CA19-9, and carcinoembryonic antigen (CEA) levels were 0.6 mg/dL, 15

78 caled-up radioiodination of a humanized anti-carcinoembryonic antigen (CEA) mAb, humanized MN-14 (hMN

79 mor targeting using a non-internalizing anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb)

80 We evaluated recombinant MV-Edm expressing carcinoembryonic antigen (CEA) or the human sodium iodid

81 we investigated the use of an enhanced human carcinoembryonic antigen (CEA) promoter for yeast cytosi

82 arget therapy to colorectal cancer using the carcinoembryonic antigen (CEA) promoter have demonstrate

83 .1-30 ng/mL) and highly (>30 ng/mL) elevated carcinoembryonic antigen (CEA) serum levels were both pr

84 We studied the behavior of three anti-carcinoembryonic antigen (CEA) single-chain Fv-Fc (scFv-

85 study, we investigated the 18F-labeled anti-carcinoembryonic antigen (CEA) T84.66 diabody, a genetic

86 ween sensitivity and specificity at specific carcinoembryonic antigen (CEA) thresholds for detecting

87 ectal cancer was generated by crossing human carcinoembryonic antigen (CEA) transgenic mice (H-2K(b))

88 and replication-defective avipox recombinant carcinoembryonic antigen (CEA) vaccines has demonstrated

89 Then the carcinoembryonic antigen (CEA) was immobilized between t

90 een patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receiv

91 sensing of cysteine, a disease biomarker and carcinoembryonic antigen (CEA), a cancer biomarker was a

92 al detection system, four cancer biomarkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP),

93 sensing (IMS) platforms for the detection of carcinoembryonic antigen (CEA), an implicated tumor biom

94 Presurgical serum fibrinogen (FIB), carcinoembryonic antigen (CEA), and carbohydrate antigen

95 sfusion, liver resection type, pre-resection carcinoembryonic antigen (CEA), and previous hepatectomy

96 d the immunogenicity of the nominal antigen, carcinoembryonic antigen (CEA), and that of an anti-idio

97 t as low as 16 pM Ebola Virus DNA, 0.01ng/mL carcinoembryonic antigen (CEA), and the 10 HER2-expressi

98 function test, and serum biomarkers such as carcinoembryonic antigen (CEA), bilirubin, alpha fetopro

99 y targeting dually acylated proteins (namely carcinoembryonic antigen (CEA), CD36, and the NH(2)-term

100 body 3H1, which mimics a specific epitope of carcinoembryonic antigen (CEA), has the potential to bre

101 he use of MVA encoding a tumor antigen gene, carcinoembryonic antigen (CEA), in addition to multiple

102 Membrane proteins, CD44, carcinoembryonic antigen (CEA), podocalyxin-like protein

103 Here we show that tolerance to carcinoembryonic antigen (CEA), which is overexpressed b

104 geting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), which subsequently also

105 In this study, using the carcinoembryonic antigen (CEA)-expressing C15 murine col

106 antitumor immune responses in patients with carcinoembryonic antigen (CEA)-expressing malignancies b

107 tion increased Fas (CD95) gene expression in carcinoembryonic antigen (CEA)-expressing murine tumor c

108 e (177)Lu is an attractive approach to treat carcinoembryonic antigen (CEA)-expressing tumors.

109 al growth factor receptor 2 (HER2)-negative, carcinoembryonic antigen (CEA)-positive metastatic breas

110 Although carcinoembryonic antigen (CEA)-related cell adhesion mol

111 In this report, two different cancer carcinoembryonic antigen (CEA)-related cell adhesion mol

112 cognizes decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell adhesion mol

113 Carcinoembryonic antigen (CEA)-related cell adhesion mol

114 arrhalis share the property of targeting the carcinoembryonic antigen (CEA)-related cell adhesion mol

115 Carcinoembryonic antigen (CEA)-related cell adhesion mol

116 nding to decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell surface prot

117 anced Raman spectroscopy (SERS) detection of carcinoembryonic antigen (CEA).

118 positron emission tomographic (PET) scan or carcinoembryonic antigen (CEA).

119 en express both cyclooxygenase-2 (COX-2) and carcinoembryonic antigen (CEA).

120 es more than that obtained by assaying serum-carcinoembryonic antigen (CEA).

121 ingle-chain Fv (scFv) antibody reactive with carcinoembryonic antigen (CEA).

122 ometry, we identify this glycoprotein as the carcinoembryonic antigen (CEA).

123 mors (e.g., colon, lung, and breast) express carcinoembryonic antigen (CEA).

124 The target biomarker was carcinoembryonic antigen (CEA).

125 target cells expressing the tumor-associated carcinoembryonic antigen (CEA).

126 e lineage, genetically engineered to produce carcinoembryonic antigen (CEA).

127 ough its high affinity for the tumour marker carcinoembryonic antigen (CEA).

128 The tumor antigen used was human carcinoembryonic antigen (CEA).

129 (KC) that encodes a protein interacting with carcinoembryonic antigen (CEA).

130 ody (scAb) specific for the tumor-associated carcinoembryonic antigen (CEA).

131 The model tumor antigen used was carcinoembryonic antigen (CEA).

132 these studies was the tumor-associated human carcinoembryonic antigen (CEA).

133 ribed for detecting cancer-related biomarker carcinoembryonic antigen (CEA).

134 sensitive detection of the tumor biomarker, carcinoembryonic antigen (CEA).

135 with a biomimetic plastic antibody film for carcinoembryonic antigen (CEA, an important biomarker in

136 Carcinoembryonic antigen (CEA, CD66e, CEACAM-5) is a cel

137 The carcinoembryonic antigen (CEAs) family consists of a lar

138 ors (CAR) specific for either hPSMA or human carcinoembryonic antigen (hCEA) and with a fusion report

139 engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) to also permit r

140 phic response (P < 0.001), decrease in serum carcinoembryonic antigen (P < 0.05), and overall surviva

141 Finally, SV40 LT-positive carcinoma of carcinoembryonic antigen 424/SV40 LT transgenic mice dis

142 positive for each antigen (HT-1080(CEA) for carcinoembryonic antigen and A431 for EGF receptor), and

143 ed at multiple levels and stained using anti-carcinoembryonic antigen and anticytokeratin antibodies.

144 determine use of tumor marker tests such as carcinoembryonic antigen and CA 15-3/CA 27.29 and associ

145 Carcinoembryonic antigen and cancer antigen 15-3 concent

146 astic lesions, compared with 35% and 50% for carcinoembryonic antigen and cytology ( P < .001 and P =

147 ins) targeting two different tumor antigens (carcinoembryonic antigen and EGF receptor).

148 antigen (PSA), PSA-alpha1-antichymotrypsin, carcinoembryonic antigen and mucin-1, including detectio

149 v-Fc variants with specificity for the tumor carcinoembryonic antigen and mutations in the FcRn-bindi

150 Billing dates of STMs (carcinoembryonic antigen and/or cancer antigen 15-3/canc

151 erapy, using a humanized (131)I-labeled anti-carcinoembryonic antigen antibody ((131)I-huA5B7), with

152 We demonstrated the determination of carcinoembryonic antigen as a model protein target in 25

153 lly developed for the sensitive detection of carcinoembryonic antigen as a tumor biomarker.

154 ologue of CEACAM1 and that rabbit anti-human carcinoembryonic antigen blocks NTHI colonization of the

155 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACA

156 CEACAM1-4S (carcinoembryonic antigen cell adhesion molecule 1, with

157 Costimulation with catecholamines, carcinoembryonic antigen cell adhesion molecule 8 (CEACA

158 Carcinoembryonic antigen cell adhesion molecule like I (

159 e epithelial cell adhesion molecule CEACAM1 (carcinoembryonic antigen cell adhesion molecule-1) is do

160 Based on the absence in mice of human carcinoembryonic antigen cell adhesion molecules, the ma

161 -principle analytes include FLAG peptide and carcinoembryonic antigen detected at physiologically rel

162 More than 80% of patients had preoperative carcinoembryonic antigen determination (ie, stages II to

163 1)In-DOTA-polyethylene glycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the

164 ntly at the discretion of the physician; and carcinoembryonic antigen every 3 months postoperatively

165 bind heparan sulfate proteoglycan (HSPG) or carcinoembryonic antigen family (CEACAM) receptors on hu

166 in vivo, the canonical receptor for MHV, the carcinoembryonic antigen family member CEACAM1a, has bee

167 P, C-CAM, CD66a, or MHVR) are members of the carcinoembryonic antigen family of cell adhesion molecul

168 Additionally, three different genes of the carcinoembryonic antigen family were induced by PPARgamm

169 the immunoglobulin (Ig) superfamily and the carcinoembryonic antigen family.

170 The vertebrate-restricted carcinoembryonic antigen gene family evolves extremely r

171 In this study, carcinoembryonic antigen got specifically bound to the a

172 % CI = 1.4418-6.905, P < 0.001, Preoperative carcinoembryonic antigen HR = 2.359, 95% CI = 1.0203-5.4

173 An anti--carcinoembryonic antigen IgG antibody (MN14) was conjuga

174 aptasensor is capable enough of determining carcinoembryonic antigen in clinical diagnostics.

175 n microarrays were demonstrated by detecting carcinoembryonic antigen in human plasma samples.

176 g of single-chain antibody fragments against carcinoembryonic antigen in LS174T tumor spheroids.

177 Although cyst fluid carcinoembryonic antigen is a very good marker for the p

178 Tumor size > or =5 cm, >3 tumor nodules, and carcinoembryonic antigen level >200 ng/mL predicted poor

179 dictors of pathologic response revealed that carcinoembryonic antigen level < or = 5 ng/mL, tumor siz

180 were tumor size larger than 3 cm (P = .005), carcinoembryonic antigen level greater than 30 ng/mL (P

181 such as tumor-to-liver volume ratio or serum carcinoembryonic antigen level, and does not correlate t

182 a mild but significant correlation to serum carcinoembryonic antigen levels and tumor-to-liver volum

183 mor lymph node metastasis, tumor number, and carcinoembryonic antigen levels independently predicted

184 otherapy utilization, metastases number, and carcinoembryonic antigen levels were similar.

185 ffective for managing patients with elevated carcinoembryonic antigen levels who were candidates for

186 patients showed a similar reduction in serum carcinoembryonic antigen levels.

187 otential of high-dose 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (MAb) combi

188 ) specific for the designated receptor human carcinoembryonic antigen on the TPMV H ectodomain.

189 sion glycolysis, or change in serum level of carcinoembryonic antigen or carbohydrate antigen 19-9 fr

190 these patients had a tumor as well as plasma carcinoembryonic antigen reduction from baseline after l

191 Immunostains for Hep Par 1 and polyclonal carcinoembryonic antigen remain important cornerstones i

192 stologically negative LNs by AE1/AE3 IHC and carcinoembryonic antigen RT-PCR.

193 otocol LTS-01 had a colonoscopy, 88.2% had a carcinoembryonic antigen test, and 66.4% had a computed

194 Medical history, physical examination, and carcinoembryonic antigen testing should be performed eve

195 origin [hazard ratio (HR) 2.04, P < 0.001], carcinoembryonic antigen value >/=5 ng/mL at hepatic res

196 L (reference range, 2.14-2.53 mmol/L), and a carcinoembryonic antigen value of 2.69 mug/L (normal val

197 Her carcinoembryonic antigen was 1.1, and all other laborato

198 CEA (carcinoembryonic antigen) protein and c-DNA were detecte

199 iety (monovalent streptavidin or antibody to carcinoembryonic antigen) to label cell-surface proteins

200 e using a multivalent, recombinant anti-CEA (carcinoembryonic antigen) x anti-HSG (histamine-succinyl

201 irally encoded marker peptide (soluble human carcinoembryonic antigen).

202 bserved radiation-induced down-regulation of carcinoembryonic antigen, a prototypic cancer biomarker.

203 rum biomarker assay, we determined levels of carcinoembryonic antigen, alpha1-antitrypsin, and squamo

204 tations or preoperative cyst fluid analysis (carcinoembryonic antigen, amylase, or mucin presence).

205 therapy responses were assessed by CT, serum carcinoembryonic antigen, and calcitonin.

206 fferentiation markers (alkaline phosphatase, carcinoembryonic antigen, and E-cadherin).

207 sion of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver st

208 as a 40-kilodalton band distinct from mucin, carcinoembryonic antigen, and Mac-2 binding protein.

209 lycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated

210 f the largest metastatic tumor, preoperative carcinoembryonic antigen, bilateral resection, extensive

211 agnetic resonance imaging, or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not

212 tic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not

213 Carcinoembryonic antigen, cancer antigen 15-3, and cance

214 h peptides from corresponding tumor antigen (carcinoembryonic antigen, CD55, and human high molecular

215 antigen, prostate-specific membrane antigen, carcinoembryonic antigen, CK-19, CK-20, mucin 1, and GA7

216 immunohistochemical markers (polyclonal anti-carcinoembryonic antigen, CK7, CK20, and alpha-fetoprote

217 care (computed tomography scan, preoperative carcinoembryonic antigen, clear surgical margins, medica

218 ed for comparison, including polyclonal anti-carcinoembryonic antigen, cytokeratin (CK) 7, CK20, and

219 nded for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesteron

220 showed good performance in the detection of carcinoembryonic antigen, exhibiting a simple, rapid and

221 r the early detection of a cancer biomarker, carcinoembryonic antigen, in the sera of mice bearing a

222 ther with tumor antigens such as survivin or carcinoembryonic antigen, markedly activate both innate

223 and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) wer

224 9, 12, and every 6 months thereafter, using carcinoembryonic antigen, physical examination, computed

225 Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha

226 nuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and

227 ed patient age, tumor location, preoperative carcinoembryonic antigen, T stage, numbers of positive a

228 marker of the secretory cell lineage, since carcinoembryonic antigen, which is expressed in both the

229 Here we have identified carcinoembryonic antigen- related cell adhesion molecule

230 Carcinoembryonic antigen-A2Kb (CEA-A2Kb) double transgen

231 ory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecu

232 onstrated an increase in Ca(2+)-independent, carcinoembryonic antigen-dependent homotypic aggregation

233 e responses were induced in a patient with a carcinoembryonic antigen-expressing adenocarcinoma after

234 Furthermore, other carcinoembryonic antigen-expressing malignancies could a

235 ctural changes within the genomic cluster of carcinoembryonic antigen-like cellular adhesion molecule

236 es (bsAbs) for disease-specific targeting of carcinoembryonic antigen-positive cells and recognition

237 e studied interactions among proteins of the carcinoembryonic antigen-related cell adhesion molecule

238 Carcinoembryonic antigen-related cell adhesion molecule

239 D complexed with its protein receptor murine carcinoembryonic antigen-related cell adhesion molecule

240 c/Akt signaling axis via an interaction with carcinoembryonic antigen-related cell adhesion molecule

241 ter hair cells (OHC) that is a member of the carcinoembryonic antigen-related cell adhesion molecule

242 f MHV NTD complexed with its receptor murine carcinoembryonic antigen-related cell adhesion molecule

243 (S) protein to bind the host receptor mouse carcinoembryonic antigen-related cell adhesion molecule

244 ptor we used the cell-cell adhesion molecule carcinoembryonic antigen-related cell adhesion molecule

245 The carcinoembryonic antigen-related cell adhesion molecule

246 target an important human cellular receptor carcinoembryonic antigen-related cell adhesion molecule

247 Liver-specific inactivation of carcinoembryonic antigen-related cell adhesion molecule

248 d insulin clearance, in liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule

249 Liver-specific inactivation of carcinoembryonic antigen-related cell adhesion molecule

250 CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

251 udies suggest an important role for CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

252 Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule

253 tudy aims to clarify the association between carcinoembryonic antigen-related cell adhesion molecule

254 Carcinoembryonic antigen-related cell adhesion molecule

255 ding of viral spike (S) proteins to cellular carcinoembryonic antigen-related cell adhesion molecule

256 Down-regulation of carcinoembryonic antigen-related cell adhesion molecule

257 Carcinoembryonic antigen-related cell adhesion molecule

258 Carcinoembryonic antigen-related cell adhesion molecule

259 Overexpression of carcinoembryonic antigen-related cell adhesion molecule

260 a 3D model of breast morphogenesis, CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

261 ls and virions, peripheral S1 fragments bind carcinoembryonic antigen-related cell adhesion molecule

262 such as S100A4, prostate stem cell antigen, carcinoembryonic antigen-related cell adhesion molecule

263 tion with the primary MHV receptor, a murine carcinoembryonic antigen-related cell adhesion molecule

264 itecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule

265 fat diet reduces the expression of CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

266 Carcinoembryonic antigen-related cell adhesion molecule

267 Human carcinoembryonic antigen-related cell adhesion molecule

268 p adhesin, exploiting defined members of the carcinoembryonic antigen-related cell adhesion molecule

269 Carcinoembryonic antigen-related cell adhesion molecule

270 Here, we identify members of the carcinoembryonic antigen-related cell adhesion molecule

271 authors found that liver grafts with absent carcinoembryonic antigen-related cell adhesion molecule

272 Carcinoembryonic antigen-related cell adhesion molecule

273 Tectorin (TECTA), beta-tectorin (TECTB), and carcinoembryonic antigen-related cell adhesion molecule

274 of Blood, Alshahrani et al demonstrate that carcinoembryonic antigen-related cell adhesion molecule

275 The carcinoembryonic antigen-related cell adhesion molecule

276 A functional role for the carcinoembryonic antigen-related cell adhesion molecule

277 Carcinoembryonic antigen-related cell adhesion molecule-

278 Although carcinoembryonic antigen-related cell adhesion molecule-

279 Carcinoembryonic antigen-related cell adhesion molecule-

280 Carcinoembryonic antigen-related cell adhesion molecule-

281 ionary origin, and function of rat and human carcinoembryonic antigen-related cell adhesion molecule1

282 -accelerating factor (DAF), collagen IV, and carcinoembryonic antigen-related cell adhesion molecules

283 transcription 1), K16 (keratin 16), CEACAMs (carcinoembryonic antigen-related cell adhesion molecules

284 Carcinoembryonic antigen-related cell adhesion molecules

285 Carcinoembryonic antigen-related cell adhesion molecules

286 hly isolated myeloma cells expressed several carcinoembryonic antigen-related cell adhesion molecules

287 Carcinoembryonic antigen-related cellular adhesion molec

288 Carcinoembryonic antigen-related cellular adhesion molec

289 were monitored for 3 mo using PET and serum carcinoembryonic antigen.

290 treatment of solid cancers known to produce carcinoembryonic antigen.

291 aving recurrence based on elevated levels of carcinoembryonic antigen.

292 ., human prostate-specific antigen and human carcinoembryonic antigen.

293 nosensor was fabricated for the detection of carcinoembryonic antigen.

294 ptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen.

295 ltaneous detection of cancer antigen 125 and carcinoembryonic antigen.

296 h node metastasis status and serum levels of carcinoembryonic antigen.

297 d Raman scattering detection of the targeted carcinoembryonic antigen.

298 Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomar

299 here we show that ETEC use LT to up-regulate carcinoembryonic antigenrelated cell adhesion molecules

300 on-typable (NTHi) H. influenzae target human carcinoembryonic antigens (the membrane associated CEA f